Drugs in Development and Experimental Approaches

Evidence based Dementia Practice

Volumn , Issue , 2008, Pages 447-457

  Emre, Murat ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0012527706     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470752340.ch32     Document Type: Chapter

References (92)

1. Abe, K., Takeyama, C., Yoshimura, K. (1998). Effects of S-8510, a novel benzodiazepine receptor partial inverse agonist, on basal forebrain lesioning-induced dysfunction in rats. European Journal of Pharmacology 347 (2-3), 145-152.
2. Aisen, P.S. & Davies, K.L. (1997) The search for diseasemodifying treatment for Alzheimer's disease. Neurology 48 (Suppl. 6), 35-41.
3. Albert, M., Jenike, M., Nixon, R. & Nobel, K. (1993) Thyrotropin response to thyrotropin-releasing hormone in patients with dementia of the Alzheimer type. Biological Psychiatry 33 (4), 267-271.
4. Alves, S.E., Wieland, N.G., Hayashi, S. & McEwen, B.S. (1998) Immunocytochemical localization of nuclear estrogen receptors and progestin receptors within the rat dorsal raphe nucleus. Journal of Comparative Neurology 391 (3), 322-334.
5. Arneric, S.P., Sullivan, J.P., Decker, M.W. et al. (1995) Potential treatment of Alzheimer disease using cholinergic channel activators (ChCAs) with cognitive enhancement, anxiolytic-like, and cytoprotective properties. Alzheimer Disease and Associated Disorders 9 (Suppl. 2), 50-61.
6. Bennett, G.W., Ballard, T.M., Watson, C.D. & Fone, K.C. (1997) Effect of neuropeptides on cognitive function. Experimental Gerontology 32 (4-5), 451-469.
7. Bierer, L.M., Aisen, P.S., Davidson, M., Ryan, T.M., Schmeidler, J., Davis, K.L. (1994) A pilot study of clonidine plus physostigmine in Alzheimer's disease. Dementia 5 (5), 243-246.
8. Bodick, N.C., Offen, W.W., Levy, A.I. et al. (1997) Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Archives of Neurology 45 (4), 465-473.
9. Bowden, M.W., Higgins, J. & Pichard, J. (1998) Effectiveness of the MAO-B inhibitor, Lazabemide (Ro 19-6327), on the progression of Alzheimer's disaese. Neurobiology of Aging 19 (4S), 185.
10. Camacho, F., Smith, C.P., Vargas, H.M., Winslow, J.T. (1996). Alpha 2-adrenoceptor antagonists potentiate acetylcholinesterase inhibitor effects on passive avoidance learning in the rat. Psychopharmacology 124 (4), 347-354.
11. Checler, F. (1995) Processing of the beta-amyloid precursor protein and its regulation in Alzheimer's disease. Journal of Neurochemistry 65, 1431-1444.
12. Cherrier, M., Asthana, S., Plymate, S. et al. (1998) Testosterone treatment in Alzheimer's disease and healthy older men. Neurobiology of Aging 19 (4S), 302.
13. Chessell, I.P., Procter, A.W., Francis, P.T. & Bowen, D.M. (1991) D-cycloserine, a putative cognitive enhancer, facilitates activation of the N-methyl-D-aspartate receptor-ionophore complex in Alzheimer brain. Brain Research 565 (2), 345-348.
14. Dekker, A.J., Winkler, J., Ray, J., Thal, L.J. & Gage, F.H. (1994) Grafting of nerve growth factor-producing fibroblasts reduces behavioral deficits in rats with lesions of the nucleus basalis magnocellularis. Neuroscience 60, 299-309.
15. Domany, G., Barta-Szalai, G., Gere, A., Farsang, G. & Schon, I. (1996) 4-(1-Naphthylamino) -piperidines as inhibitors of lipid peroxidation. Arzneimittelforschung 46 (6), 553-556.
16. Dore, S., Kar, S. & Remi, Q. (1997) Rediscovering an old friend, IGF-1: potential use in the treatment of neurodegenerative diseases. Trends in Neuroscience 20, 326-331.
17. Drug and Market Development (1998) Progress in the understanding and treatment of Alzheimer's disease. Drug and Market Development 9, 235-239.
18. Dysken, M.W. & Kuskowski, M. (1998) Ondansetron in the treatment of cognitive decline in Alzheimer's dementia. Neurobiology of Aging 19 (4S), 178.
19. Fabrazzo, M., Costa, E. & Mochetti, I. (1991) Stimulation of nerve growth factor biosynthesis in developing rat brain by reserpine: steroids as potential mediators. Molecular Pharmacology 39 (2), 144-149.
20. Fakouhi, T.D., Jhee, S.S., Sramek, J.J. et al. (1995) Evaluation of cycloserine in the treatment of Alzheimer's disease. Journal of Geriatric Psychiatry and Neurology 8 (4), 226-230.
21. Fischer, W., Wictorin, K., Bjorklund, A., Williams, L.R., Varon, S. & Gage, F.H. (1987) Ameloriation of cholinergic neuron atrophy and spatial memory impairment in aged rats by nerve growth factor. Nature 329 (6134), 65-68.
22. Fischhof, P.K., Moslinger-Gehmayr, R., Herrmann, W.M., Friedmann, A. & Russmann, D.L. (1996). Therapeutic efficacy of vincamine in dementia. Neuropsychobiology 34 (1), 29-35.
23. Fleming, L.M. & Johnson, G.V. (1995) Modulation of the phosphorylation state of tau in situ: the roles of calcium and cyclic AMP. Biochemistry Journal 309 (1), 41-47.
24. Geerts, H., Nuydens, R., De Jong, M. et al. (1996) Sabeluzole stabilizes the neuronal cytoskeloton. Neurobiology of Aging 4 (17), 578-581.
25. Genis, I., Fisher, A., Shohami, E. & Michaelson, D.M. (1999) Modulation of tau hyperphosphorylation in ApoE-deficient mice by muscarinic activation and closed head injury. In: Alzheimer's Disease and Related Disorders (eds Iqbal, K. et al.), pp. 733-740. John Wiley, Chichester.
26. Glasky, A.J., Melchior, C.L., Pirzadeh, B., Heydari, N. & Ritzmann, R.F. (1994) Effect of AIT-082, a purine analog, on working memory in normal and aged mice. Pharmacological Biochemistry and Behavior 47, 325-329.
27. Gozes, I., Bardea, A. & Reshef, R. (1996) Novel neuroprotective strategy for Alzheimer's disease: inhalation of fatty neuropeptides. Proceedings of the National Academy of Sciences of the USA 93, 427-432.
28. Gutzmann, H. & Hadler, D. (1998) Sustained efficacy and safety of idebenone in the treatment of Alzheimer's disease: update on a 2-year double-blind multicentre study. Journal of Neural Transmission 54 (Suppl.), 301-310.
29. Haas, S., Vincent, K., Holt, J. & Lippmann, S. (1997) Divalproex: a possible treatment alternative for demented, elderly aggressive patients. Annals of Clinical Psychiatry 9 (3), 145-147.
30. Hagg, T., Fass-Holmes, B., Valshing, H.L., Manthrope, M., Corner, J.M. & Varon, S. (1989) Nerve growth factor (NGF) reverses axotomy-induced decreases in choline acetyltransferase, NGF receptor and size of medial septum cholinergic neurons. Brain Research 505, 29-38.
31. Harder, J.A., Maclean, C.J., Alder, J.T., Francis, P.T. & Ridley, R.M. (1996) The 5-HT1A antagonist, WAY 100635, ameliorates the cognitive impairment induced by fornix transection in the marmoset. Psychopharmacology (Berlin) 127 (3), 245-254.
32. Herrmann, W.M., Stephan, K., Gaede, K. & Apeceche, M.A. (1997) Multicenter randomized double-blind study on the efficacy and safety of nicergoline in patients with multi-infarct dementia. Dementia and other Geriatric Cognitive Disorders 8 (1), 9-17.
33. Howlet, D. (1997) Hemin and related porphyrins inhibit beta-amyloid aggregation. FEBS Letters 417 (2), 249-251.
34. Huang, D.Y., Goedert, M., Jakes, R. et al. (1994) Isoform-specific interactions of apolipoproteinE with the microtubule-associated protein MAP2c: implications for Alzheimer's disease. Neuroscience Letters 182 (55), 55-58.
35. Huff, F.J. (1996) Preliminary evaluation of besipirdine for the treatment of Alzheimer's disease. Besipirdine Study Group. Annals of the New York Academy of Sciences 777, 410-414.
36. Iqbal, K. (1996) Molecular mechanism of Alzheimer's neurofibrillary degenaration and therapeutic intervention. Annals of New York Academy of Sciences 777, 132-138.
37. Jakala, P., Riekkinen, M., Sirvio, J. et al. (1999a) Guanfacine, but not clonidine, improves planning and working memory performance in humans. Neuropscyhopharmacology 20 (5), 460-470.
38. Jakala, P., Sirvio, J., Riekkinen, M. et al. (1999b) Guanfacine and clonidine, alpha 2-agonists, improve paired associates learning, but not delayed matching to sample, in humans. Neuropscyhopharmacology 20 (2), 119-130.
39. Kaplitt, M., Fass-Holmes, B., Vahlsing, H.L., Manthrope, M., Conner, J.M. & Varon, S. (1996) Apolipoprotein E, beta-amyloid, and the molecular pathology of Alzheimer's disease: therapeutic implications. Annals of the New York Academy of Science 802, 42-49.
40. Kem, W.R. (1997) Alzheimer's drug design based upon an invertebrate toxin (anabaseine) which is a potent nicotinic receptor agonist. Invert Neuroscience 3 (2-3), 251-259.
41. Kihara, T., Shimohama, S. & Akaike, A. (1999) Nicotine receptor stimulation protects neurons against glutamateand amyloid-B-induced cytotoxicity. In: Alzheimer's Disease and Related Disorders (eds Iqbal, K. et al.), pp. 715-722. John Wiley, Chichester.
42. Kitagawa, H., Moriyama, A., Takenouchi, T., Wesnes, K., Kramer, W. & Clody, D.E. (1998) Phase I studies of GTS-21 to assess the safety, tolerability, PK and effects on measures of cognitive function in normal volunteers. Neurobiology of Aging 19 (4S), 182.
43. Kumar, V., Cameron, A.M. & Amrein, R. (1998) Experience with the RIM-B Lazabemide in Alzheimer's disease. Neurobiology of Aging 19 (4S), 328.
44. Lee, V.M.Y. (1996) Regulation of tau phosphorylation in Alzheimer's disease. Annals of the New York Academy of Sciences 777, 107-113.
45. Leszek, J., Inglot, A.D., Janusz, M. & Lisowski, J. (1998) Oral cytokine administration-therapeutic approaches to Alzheimer's disease. Neurobiology of Aging 19 (4S), 180.
46. Levy, M.L., Cummings, J.L. & Kahn Rose, R. (1999) Neuropsychiatric symptoms and cholinergic therapy for Alzheimer's disease. Gerontology 45 (Suppl. 1), 15-22.
47. Lopez Pousa, S., Mercadal Dalmau, J., Marti Cuadros, A.M., Vilalta Franch, J. & Lozano Gallego, M. (1997) Trifusal in the prevention of vascular dementia. Revue Neurologique 25 (146), 1525-1528.
48. Lorenzo, A. & Yankner, B.A. (1994) Beta-amyloid neurotoxicity requires fibril formation and is inhibited by Congo Red. Proceedings of the National Academy of Sciences of the USA 91, 12 243-12 247.
49. Lynch, G., Granger, R., Ambros-Ingerson, J., Davis, C.M., Kessler, M. & Schehr, R. (1997) Evidence that a positive modulator of AMPA-type glutamate receptors improves delayed recall in aged humans. Experimental Neurology 145 (1), 89-92.
50. Markowska, A.L., Koliatsos, V.E., Breckler, S.J., Price, D.L. & Otton, D.S. (1994) Human nerve growth factor improves spatial memory in aged but not young rats. Journal of Neuroscience 14, 4815-4824.
51. Martinez-Serano, A., Fischer, W. & Bjorklund, A. (1995) Reversal of age dependant cognitive impairments and cholinergic neuron atrophy by NGF-secreting neuronal progenitors grafted to the basal forebrain. Neuron 15, 473-484.
52. Middlemiss, P.J., Glasky, A.J., Rathbone, M.P., Werstuik, E., Hindley, S. & Gyspers, J. (1995) AIT-082, a unique purine derivative, enhances nerve growth factor mediated neurite outgrowth from PC12 cells. Neuroscience Letters 199, 131-134.
53. Miguel-Hidalgo, J.J., Alvarez, X.A., Quack, R. & Cacabelos, R. (1998) Protection by memantine against A-beta (1-40) - induced neurodegenaration in the CA1 subfield. Neurobiology of Aging 19 (4S), 129.
54. Miyamoto, M., Hirai, K., Heya, T. & Nagaoka, A. (1994). Effects of a sustained release formulation of thyrotropinreleasing hormone on behavioral abnormalities in senescence-accelerated mice. European Journal of Pharmacology 271 (2-3), 357-366.
55. Miyata, M. & Smith, J.D. (1996) Apolipoprotein E allelespecific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nature (Genetics) 15, 55-61.
56. Mohr, E., Nair, N.P., Sampson, M. et al. (1997) Treatment of Alzheimer's disease with sabeluzole: functional and structural correlates. Clinical Neuropharmacology 20 (4), 338-345.
57. Molto, J.M., Falip, R., Martin, R., Insa, R., Pastor, I. & Matias Guiu, J. (1995) Comparative study of nicardipine versus placebo in the prevention of cognitive deterioration in patients with transient ischemic attack. Revue Neurologique 23 (119), 54-58.
58. Moser, P.C., Bergis, O.E., Santamaria, R. et al. (1998) SL65.0102, a novel and selective partial agonist at 5-HT4 receptors improves learning and memory in rodents. Neurobiology of Aging 19 (4S), 262.
59. Nabeshima, T. (1995) Nerve growth factor strategy and preparation of animal model for Alzheimer-type senile dementia. Yakugaku Zasshi 115 (7), 499-512.
60. Nakata, M. (1996) Electrophysiological evaluation of the demented state and the nootropic effect of TA-0910 by automated fluctuation analysis of the high frequency EEG. Relation between neuropsychological test results and Lorentzian parameters. No To Shinkei 48 (6), 551-558.
61. Nitta, A., Murakami, Y., Furukawa, Y. et al. (1994) Oral administration of idebenone induces nerve growth factor in the brain and improves learning and memory in basal forebrain-lesioned rats. Naunyn Schmiedebergs Archives of Pharmacology 349 (4), 401-407.
62. Nuydens, R., De Jong, M., Nuyens, R., Cornelissen, F. & Geerts, H. (1995) Neuronal kinase stimulation leads to abberant tau phosphorylation and neurotoxicity. Neurobiology of Aging 16, 465-475.
63. Ogasawara, T., Itoh, Y., Tamura, M., Ukai, Y. & Kimura, K. (1996) NS-3, a TRH-analog, reverses memory disruption by stimulating cholinergic and noradrenergic systems. Pharmacological Biochemistry and Behavior 53 (2), 391-399.
64. Olson, L., Nordberg, A., von Holst, H. et al. (1992) Nerve growth factor affects 11c-nicotinic binding, blood flow, EEG, and verbal episodic memory in an Alzheimer patient. Journal of Neural Transmission Parkinson Disease Dementia Section 4 (1), 79-95.
65. Pappolla, M.A., Chyan, Y.J., Bozner, P et al. (1999) Dual anti-amyloidogenic and anti-oxidant properties of melatonin: a new therapy for Alzheimer's disease. In: Alzheimer's Disease and Related Disorders (eds Iqbal, K. et al.), pp. 661-669. John Wiley, Chichester.
66. Parnetti, L., Ambrosoli, L., Abete, G. et al. (1995) Posatirelin for the treatment of late-onset Alzheimer's disease: a double-blind multicentre study vs citicoline and ascorbic acid. Acta Neurologica Scandinavica 92 (2), 135-140.
67. Parnetti, L., Ambrosoli, L., Agliati, G. et al. (1996) Posatirelin in the treatment of vascular dementia: a double-blind multicentre study vs placebo. Acta Neurologica Scandinavica 93 (6), 456-463.
68. Parnetti, L., Mari, D., Abate, G. et al. (1997b) Vascular dementia Italian sulodexide study (VA.D.I.S.S.). Clinical and biological results. Thrombosis Research 87 (2), 225-233.
69. Parnetti, L., Senin, U. & Mecocci, P. (1997a) Cognitive enhancement therapy for Alzheimer's disease. The way forward. Drugs 53 (5), 752-768.
70. Racchi, M., Schmidt, B., Koenig, G. & Govoni, S. (1999) Treatment with metrifonate promotes soluble amyloid precursor protein release from SH-SY5Y neuroblastoma cells. In: Alzheimer's Disease and Related Disorders (eds Iqbal, K. et al.), pp. 679-688. John Wiley, Chichester.
71. Sarter, M., Bruno, J.P. (1997) Trans-synaptic stimulation of cortical acetylcholine and enhancement of attentional functions: a rational approach for the development of cognition enhancers. Behavioural Brain Research 83 (1-2), 7-14.
72. Schenk, D.B., Rydel, R.E., May, P. et al. (1995) Therapeutic approaches related to amyloid-beta peptide and Alzheimer's disease. Journal of Medical Chemistry 38 (21), 4141-4154.
73. Schenk, D., Barbour, R., Dunn, W. et al. (1999) Immunization with amyloid-beta attenuates Alzheimerdisease- like pathology in the PDAPP mouse. Nature 400 (July 8), 173-177.
74. Schwartz, B.L., Hashtroudi, S., Herting, R.L., Schwartz, P., Deutsch, S.I. (1996) d-Cycloserine enhances implicit memory in Alzheimer patients. Neurology 46 (2), 420-424.
75. Shrotriya, R.C., Cutler, N.R., Sramek, J.J., Veroff, A.E., Hironaka, D.Y. (1996) Efficacy and safety of BMY 21 502 in Alzheimer disease. Annals of Pharmacotherapy 30 (12), 1376-1380.
76. Solomon, B., Koppel, R., Hanan, E. & Katzav, T. (1996) Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide. Proceedings of the National Academy of Sciences of the USA 93 (1), 452-455.
77. Soto, C., Sgurdsson, E.M., Morelli, L. et al. (1999) Betasheet breaker peptides prevent the formation of fibrillar amyloid-beta deposits. In: Alzheimer's Disease and Related Disorders (eds Iqbal, K. et al.), pp. 729-732. John Wiley, Chichester.
78. Strittmatter, W.J., Weisgraber, K.H. & Goudert, M. (1994) Hypothesis: microtubule instability and paired helical filament formation in the Alzheimer disease brain are related to apolipoprotein E genotype. Experimental Neurology 125 (1), 163-171.
79. Strittmatter, W.J., Weisgraber, K.H., Huang, D.Y. et al. (1993) Binding of human apolipoprotein E to synthetic amyloid beta-peptide: isoform specific effects and implication for late-onset Alzheimer's disease. Proceedings of the National Academy of Sciences of the USA 90, 8098-8102.
80. Thorne, R.G., Wilsont, S.J., Fawcett, J.R., Ala, T.A. & Frey, W.H. (1998) Delivery of insulin-like growth factor-1 (IGF-1) to the brain via the olfactory pathway: a possible therapeutic strategy for Alzheimer's disease. Neurobiology of Aging 19 (4S), 260.
81. Tomiyamo, T., Shoji, A., Kataoka, K. et al. (1996) Inhibition of amyloid beta protein aggregation and neurotoxicity by rifampicine: its possible function as a hydroxyl radical scavenger. Journal of Biological Chemistry 271 (12), 6839-6844.
82. Tozawa, K., Mishima, K., Satoh, K. et al. (1998) Melatonin replacement therapy for rest-activity rhythm disorders in patients with senile dementia of Alzheimer's type. Neurobiology of Aging 19 (4S), 182.
83. Tsai, G.E., Falk, W.E., Gunther, J., Coyle, J.T. (1999) Improved cognition in Alzheimer's disease with shortterm D-cycloserine treatment. American Journal of Psychiatry 156 (3), 467-469.
84. Uberti, D., Rizzini, C., Galli, P. et al. (1997) Priming of cultered neurons with sabeluzole results in long-lasting inhibition of neurotoxin-induced tau expression and cell death. Synapse 26 (2), 95-103.
85. Wang, J.Z., Grundke-Iqbal, I. & Iqbal, K. (1996) Restoration of biological activity of Alzheimer abnormally phosphorylated tau by dephosphorylation with protein phosphatase-2A, -2B and -1. Brain Research. Molecular Brain Research 38 (2), 200-208.
86. Wenk, G.L., Danysz, W. & Mobley, S.L. (1994) Investigations of neurotoxicity and neuroprotection within the nucleus basalis of the rat. Brain Research 655, 7-11.
87. Weyer, G., Babej D'lle, R.M., Hadler, D., Hofmann, S. & Herrmann, W.M. (1997) A controlled study of 2 doses of idebenone in the treatment of Alzheimer's disease. Neuropsychobiology 36 (2), 73-82.
88. Winblad, B. & Poritis, N. (1998) Clinical improvement in a placebo-controlled trial with memantine in caredependent patients with severe dementia. Neurobiology of Aging 19 (4S), 302.
89. Xu, H., Gauras, G.K., Greenfield, J.P. et al. (1998) Estrogen reduces neuronal generation of Alzheimer beta-amyloid peptides. Nature (Medicine) 4 (4), 447-451.
90. Xu, H.X., Greengard, P. & Gandly, S. (1995) Regulated formation of Golgi secretory vesicles containing Alzheimer beta-amyloid precursor protein. Journal of Biological Chemistry 270, 23243-23245.
91. Yamada, K., Nitta, A., Hasegawa, T. et al. (1997) Orally active NGF synthesis stimulators: potential therapeutic agents in Alzheimer's disease. Behavioral Brain Research 83 (1-2), 117-122.
92. Zajaczkowski, W., Frankiewicz, T., Parsons, C.G. & Danysz, W. (1997) Uncompetitive NMDA receptor antagonists attenuate NMDA-induced impairment of passive avoidance learning and LTP. Neuropharmacology 36, 961-971